3-Tesla MRI Response to TACE in HCC (Liver Cancer)

Inclusion Criteria:

- Subjects must have signed an institutional review board (IRB)-approved informed
consent document

- Subjects must have verified unresectable hepatocellular carcinoma (HCC), diagnosed on
the basis of clinical and imaging criteria

- Subjects must be classified as TNM stage I, II, or III; alternatively, subjects may be
classified as Barcelona Clinic Liver Cancer (BCLC) stage A or B

- Subjects must be scheduled to undergo transarterial chemoembolization (TACE)

- Subjects must have at least 1 lesion being targeted by TACE that is > 2 cm in the
longest cross-sectional (axial plane) diameter

- Subjects must satisfy one of the following conditions pertaining to their eligibility
to undergo orthotopic liver transplantation (OLT):

- HCC that is within Milan Criteria, i.e., TACE is indicated as a "bridge" to OLT
(Group I); or

- HCC that is outside Milan Criteria, i.e., TACE is indicated as a means of
"down-staging" into transplant eligibility (Group II)

Exclusion Criteria:

- Subjects who have received prior treatment for HCC (prior surgical procedures not
related to HCC are allowed)

- Subjects who have undergone prior radioembolization

- Subjects with a central venous line

- Subjects who have any type of biomedical implant, device and/or ferromagnetic material
that can be displaced, perturbed, or otherwise malfunction due to mechanical,
electronic, or magnetic means; these items may include:

- Metallic fragments or shrapnel (such as from war wounds)

- Cerebral aneurysm clips, biopsy marker clips

- Vascular access ports (as are used with intravenous chemotherapy)

- Cochlear implants, pacemakers, neurostimulators, biostimulators, and electronic
infusion pumps **Implanted materials other than those verified as being rated
"magnetic resonance [MR] Safe" or "MR Conditional 6" will not be allowed on study

- Creatinine >= 1.5 times upper limit of normal

- Estimated glomerular filtration rate (eGFR) < 30 mL/min

- Subjects who are pregnant or nursing

- Subjects who have had past allergic or other adverse reactions to intravenous
injection of Magnevist® (gadopentetate dimeglumine) or other gadolinium-containing
contrast agents

- Subjects who exhibit noticeable anxiety, claustrophobia, or vertigo when moved into
the scanner

- Subjects incapable of giving informed written consent, for the following reasons:

- Inability to adhere to the experimental protocols for any reason

- Inability to communicate with the research team

- Mental disability, altered mental status, confusion, or psychiatric disorders

- Prisoners or others susceptible to coercion